The Wolverine research blend: BPC-157 and TB-500
Research Blends
Research Peptide Learning Centre · Published 7 October 2026 · 4 min read
What the Wolverine research blend contains, how each component is studied in the literature, and the documentation to check before a laboratory comparison.
“Wolverine” is a research blend that combines two peptides in a single vial: BPC-157 and TB-500 (Thymosin beta-4). This guide explains what is in it, what each component has actually been studied for, and how to read the records. It is educational and is not a route to personal use or a statement that any activity is permitted.
What is in the Wolverine blend
The Reforge listing states BPC-157 5 mg and TB-500 5 mg, for 10 mg of peptide content per vial (see the Wolverine research profile). A blend brings together two separately studied materials; it does not create a third, combined compound with its own validated effect. Each component has its own literature, and a result for one is not evidence for the pair.
BPC-157: what the research examined
BPC-157 is a 15-amino-acid peptide examined in experimental tissue-response models. A 2011 study of rat Achilles tendon explants and fibroblasts reported changes in cell outgrowth, migration and survival under stress, while cell proliferation was not directly increased in the assay (Chang et al., 2011). Those are defined cell endpoints, not evidence that a vial improves injury recovery in people. For the listing and its documentation status, see the BPC-157 research profile and the BPC-157 research guide.
TB-500 (Thymosin beta-4): what the research examined
TB-500 is the research name for Thymosin beta-4, a 43-amino-acid peptide that binds and sequesters actin. Reviews describe its role in actin regulation and tissue-repair models (Goldstein et al., 2005), and an earlier study reported accelerated wound closure in animal models (Malinda et al., 1999). These are laboratory and animal findings. See the TB-500 research profile and the TB-500 research guide.
The blend versus two single-compound vials
A two-component blend fixes the ratio of its parts. Wolverine holds BPC-157 and TB-500 at a set 5 mg and 5 mg; separate BPC-157 and TB-500 vials let a protocol record each amount independently. Neither arrangement implies the two materials act together. The practical difference for a laboratory comparison is documentation: one vial carries one lot and, when published, one certificate covering the mixture, while two vials carry two lots and two reports. Record whichever applies, and keep each component’s identity traceable to its own analysis rather than inferring it from the blend’s label.
How a blend is tested, and what a certificate can and cannot show
For any laboratory comparison, record each component’s identity, match the proposed lot to its analytical report, and note the laboratory, method, result and date. A certificate for a blend reports what was measured on that mixture; it does not establish that two materials interact or that combining them is appropriate for a given method. Mark every requirement as supplied, pending or not applicable. A batch-specific certificate of analysis is not yet published for the Wolverine blend, and no purity percentage is claimed for it.
A research-use label does not settle regulatory questions. Health Canada’s advisory on online injectable peptides states that research-use wording does not exempt products from regulatory requirements. Read the advisory. The COA guide and the Certificate Library cover the analytical side.
Common questions
What is in the Wolverine blend?
The listing states BPC-157 5 mg and TB-500 (Thymosin beta-4) 5 mg, for 10 mg of peptide content per vial.
Does combining BPC-157 and TB-500 create a combined effect?
Each component is studied separately in the literature. Combining them in one vial does not establish a combined effect, and no combined pharmacology is claimed.
Is there a certificate of analysis for Wolverine?
A batch-specific certificate is not yet published for this blend, and no purity percentage is claimed. When one is released, it will be connected to the corresponding lot.
How is the blend different from buying the two peptides separately?
The blend fixes the ratio at 5 mg and 5 mg in one vial with one lot; separate vials let a protocol record each amount and lot independently. Neither arrangement means the two materials act together.
Is Wolverine intended for human use?
No. It is presented for laboratory and analytical research only, and this guide is not a treatment or personal-use protocol.
Sources and scope
- Chang et al., 2011 — BPC-157 and tendon healing: outgrowth, survival and migration (J Appl Physiol)
- Goldstein et al., 2005 — Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues (Trends Mol Med)
- Malinda et al., 1999 — Thymosin beta4 accelerates wound healing (J Invest Dermatol)
- Health Canada: advisory on unauthorized injectable peptides
Published research describes the material and conditions used by its authors. It does not test, certify or endorse Reforge inventory. This guide is educational and is not a treatment or personal-use protocol.